In the span of a single month, board reshuffles or senior management changes have occurred at no fewer than 14 pharmaceutical firms, including FOSUN PHARMA, HENGRUI PHARMA, BEIGENE, HBM HOLDINGS-B, Boan Biotech, Tonghua Dongbao, Hualan Vaccine, Zai Lab, Tongrentang, KPC Pharmaceuticals, AstraZeneca PLC China, Pfizer China, Novartis China, and Fresenius Kabi China. These moves signal significant strategic shifts within the industry.

Domestic pharmaceutical companies and biotech firms are experiencing executive transitions. The changes at HENGRUI PHARMA, Zai Lab, BEIGENE, HBM HOLDINGS-B, and FOSUN PHARMA reflect the varying developmental stages of China's innovative drug sector. The first three companies ranked among the top 10 in innovative drug revenue for 2025, securing the 2nd, 10th, and 1st positions respectively.

HENGRUI PHARMA reported innovative drug revenue of 16.342 billion yuan in 2025, accounting for 52% of total revenue. In the first quarter of 2026, this proportion exceeded 60%, with revenue reaching 4.526 billion yuan, a year-on-year increase of 25.75%. The company has set a target for 2026 of achieving over 30% growth in innovative drug sales revenue. Against this backdrop, HENGRUI PHARMA requires both R&D leadership for sustained breakthroughs and commercial/globalization experts to drive expansion. On April 16, the company announced the appointment of its new board and management team. On the R&D front, Zhu Guoxin was elected Senior Vice President; he joined in December 2025, bringing over 30 years of global cross-functional drug discovery leadership experience, previously serving as Vice President of Lilly's New Drug R&D Center. For commercialization and internationalization, Feng Ji was elected President and COO; she previously held roles as Vice President for AstraZeneca Asia and Senior Vice President of Global Commercial Insights & Business Excellence, joining HENGRUI PHARMA in April 2025. Within just one year, Feng Ji's annual salary became the highest among the company's executives at 6.5362 million yuan, underscoring her value and the company's emphasis on commercial and international talent. Following her appointment, HENGRUI PHARMA achieved a further international breakthrough by securing a licensing agreement with GSK potentially worth up to $12 billion in milestones and sales royalties. She also led the optimization of the company's global management structure and expanded its presence in Southeast Asian markets.

On April 28, Wang Yizhe joined Zai Lab as Operating Partner, Global Chief Commercial Officer, and General Manager for Greater China. With a career spanning Bristol Myers Squibb, GlaxoSmithKline, and Eli Lilly, Wang is a versatile professional experienced in R&D, product development, commerce, and management. Having successfully transitioned from a startup biotech to a biopharma, Zai Lab reported innovative drug revenue of 3.2 billion yuan in 2025. Its current challenge is evolving from simply "selling drugs" to "selling drugs effectively and profitably." Wang's appointment is seen as a crucial piece in enhancing the company's commercial efficiency and accelerating product sales growth. It is reported that during his tenure at Lilly China, he facilitated the successful launch of five new products within 16 months.

In 2025, BEIGENE achieved innovative drug revenue of 37.8 billion yuan, a 40% year-on-year increase, marking its first annual profit. For Q1 2026, innovative drug revenue reached 10.321 billion yuan, up 29.3% year-on-year, with the company maintaining a stable profit. On April 17, BEIGENE announced its slate of director nominees for the 2026 Annual General Meeting, including Felix J. Baker, Olivier Brandicourt, Margaret Dugan, Anthony C. Hooper, Elizabeth F. Mooney, John V. Oyler, Alessandro Riva, Charles L. Sawyers, Shalini Sharp, and Wang Xiaodong. This diverse list of candidates, covering R&D, operations, capital, and management, clearly aims to address the company's needs in commercialization and sophisticated operations as it evolves into a biopharma.

On April 16, HBM HOLDINGS-B announced the appointment of Zong Chen as Company President, marking the first creation of this role in the company's nearly decade-long history. This move follows a year of explosive growth and accelerated strategy in 2025. The company reported revenue of $158 million for 2025, a threefold increase year-on-year, and net profit of 650 million yuan, a 33-fold surge. HBM HOLDINGS-B plans to maintain revenue growth of at least 40-50% in 2026. Zong Chen's appointment is intended to provide critical support for pipeline strategy and external collaborations. He previously served as founding CEO leading global business development for HENGRUI PHARMA's US subsidiary and held senior roles at Merck Sharp & Dohme, Bristol Myers Squibb, and Pfizer, managing global business segments, overseeing large commercial portfolios, and leading major business development, licensing, and M&A transactions.

On April 2, FOSUN PHARMA announced a change in its Chief Financial Officer. Chen Zhanyu resigned as CFO due to work arrangement adjustments but will continue serving as Senior Vice President. The board appointed Huang Zhi as Senior Vice President, CFO, and Co-President of the Innovative Drug Business Division. FOSUN PHARMA stated that driven by the "dual engines" of innovative R&D breakthroughs and global system upgrades, it achieved innovative drug revenue of 9.893 billion yuan in 2025 (33.16% of pharmaceutical revenue) and overseas revenue of 12.977 billion yuan (31.15% of total revenue). The company's internationalization process is advancing from "product出海" to "system出海." Huang Zhi's background aligns closely with this trajectory; he spent over 13 years at Novartis Pharmaceuticals, holding positions such as Head of Business Process & Control and Head of Business Planning & Analysis for Greater China, followed by more than four years at BEIGENE as CFO for Greater China and Finance Head for the Innovation Center, where he was deeply involved in global commercial expansion. Prior to joining FOSUN PHARMA, he served as Global Senior Vice President of Business Development & Finance at Ascentage Pharma.

Beyond domestic firms, multinational pharmaceutical giants have also undergone personnel changes. At Novartis China, on May 1, Liu Zhengya, formerly Head of Solid Tumors for Novartis Japan, joined the China team as Oncology Therapeutic Area Head. On April 1, Xu Wei, Head of Neuroscience and Transplant for Novartis China, additionally assumed the role of Interim Head of Immunology.

At AstraZeneca PLC China, on April 21, former Assistant Vice President and Feiying Business Unit Head Yan Huaguo departed, later joining Hansoh Pharmaceutical as Vice President of Channel Operations Development and the Metabolic Business Unit. Sun Fangfang, formerly Central Region Sales Executive Director for the Cardiovascular, Renal, and Metabolism Business Unit at AstraZeneca PLC China, succeeded him as Head of the Feiying Business Unit. Just one month prior to Yan's departure, AstraZeneca PLC China established a new Biopharmaceutical Business Unit encompassing all product channels, appointing Yang Shengbin, Vice President of AstraZeneca PLC China, as its head. The Feiying Business Unit was integrated into this new structure, with Yan reporting to Yang.

At Fresenius Kabi China, on April 3, Zhang Wei, former Managing Director of Merck China's Healthcare business, was appointed President and Chairman of Fresenius Kabi China.

In early April, Liu Jing, General Manager of the Inflammation & Immunology Business Unit at Pfizer China, resigned and subsequently joined Zai Lab as Senior Vice President and Head of the Immunology Business Unit. Zhang Jianhui, current General Manager of the Broad Market Business Unit at Pfizer China, will temporarily assume the role of General Manager for the Inflammation & Immunology Business Unit.

Domestic pharmaceutical companies are strategically bolstering their talent pools in R&D, commerce, and finance to support their transitions from biotech to biopharma or to advance further in innovation and internationalization. Concurrently, these domestic innovative drug firms are demonstrating a strong appeal for talent from multinational corporations.